Entheon Biomedical Corp. (CNSX:ENBI) announced a non-brokered private placement of 4,266,997 units at a price of CAD 0.75 for gross proceeds of CAD 3,200,247.75 on December 18, 2020. The transaction will involve participation from strategic investors. Each unit will consist of one common share in the capital of the company and one-half of one non-transferable share purchase warrant. Each whole warrant will be exercisable to acquire one additional share at an exercise price of CAD 1 per share for a period of 24 months from the date of issuance, subject to accelerated expiry. In the event that, after four months and one day from issuance, the company's common shares trade at a closing price at or greater than CAD 1.50 per share for a period of 10 consecutive trading days, the company may accelerate the expiry date of the warrants by giving notice to the holders thereof, and in such case, the warrants will expire on the 30th day after the date on which such notice is given by the company. All securities issued under the transaction will be subject to a four month and one-day hold period and the company may pay finder's fees. The transaction is expected to close on December 23, 2020.